Antimicrobial

Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB DermatologyKane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology

Kane to Host Investor Webinar – What Kane has in Store for 2025 Including the Acquisition of FB Dermatology

Thursday, January 23rd, 2025 at 4:15pm Eastern TimeWINNIPEG, Manitoba, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE;…

3 months ago
Pacira BioSciences Strengthens Executive Leadership Team with Two Key AppointmentsPacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

Pacira BioSciences Strengthens Executive Leadership Team with Two Key Appointments

-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to…

3 months ago
Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act’s Medicare Negotiation ProgramBausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program

Bausch Health Statement on Selection of XIFAXAN(R) (rifaximin) for Inflation Reduction Act’s Medicare Negotiation Program

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business,…

3 months ago
BioWorld by Clarivate Releases Comprehensive 2024 Year in ReviewBioWorld by Clarivate Releases Comprehensive 2024 Year in Review

BioWorld by Clarivate Releases Comprehensive 2024 Year in Review

Series Recaps Biopharma, MedTech, and Science Trends and Breakthroughs That Shaped the Year LONDON, Jan. 16, 2025 /PRNewswire/ -- BioWorld™…

3 months ago
Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical OrganizationPacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

Pacira Announces New Five-Year Objectives to Accelerate Transition into an Innovative Biopharmaceutical Organization

Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc.…

3 months ago
Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate UpdatesSeres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 promoted epithelial…

4 months ago
Teleflex awarded Short Term Central Venous Catheters contract from VizientTeleflex awarded Short Term Central Venous Catheters contract from Vizient

Teleflex awarded Short Term Central Venous Catheters contract from Vizient

Including market leading Arrow™ CVCs and Arterial CathetersWAYNE, Pa., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a…

4 months ago
Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic DetectionChungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection

Chungnam National University Researchers Develop A Rapid Water Quality Monitoring Chip for Antibiotic Detection

DAEJEON, South Korea, Dec. 20, 2024 /PRNewswire/ -- Antimicrobial resistance (AMR) is a growing global health crisis because of microbes,…

4 months ago
SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

JERSEY CITY, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to…

4 months ago
Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune DiseasesNeutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

Neutrolis Expands Senior Leadership Team to Drive Development of Growing Pipeline of Non-Immunosuppressive Therapies for NET-mediated Autoimmune Diseases

Appointment of seasoned executives with substantial industry expertise strengthens team as the company advances programs into the clinicCAMBRIDGE, Mass., Dec.…

4 months ago